Novel inhibitors of bacterial protein synthesis: Structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 12, 2004, Pages 3299-3302

  Clark, Richard F ^a   Wang, Sanyi ^a   Ma, Zhenkun ^a   Weitzberg, Moshe ^a   Motter, Christopher ^a   Tufano, Michael ^a   Wagner, Rolf ^a   Gu, Yu Gui ^a   Dandliker, Peter J ^a   Lerner, Claude G ^a   Chovan, Linda E ^a   Cai, Yingna ^a   Black Schaefer, Candace L ^a   Lynch, Linda ^a   Kalvin, Douglas ^a   Nilius, Angela M ^a   Pratt, Steve D ^a   Soni, Niru ^a   Zhang, Tianyuan ^a   Zhang, Xiaolin ^a   Beutel, Bruce A ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,8 NAPHTHYRIDINE DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CIPROFLOXACIN; LEVOFLOXACIN; NAPHTHYRIDINE DERIVATIVE; NAPHTHYRIDONE; NORFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CELL PERMEABILIZATION; CONTROLLED STUDY; DRUG PENETRATION; DRUG POTENCY; DRUG SYNTHESIS; HAEMOPHILUS INFLUENZAE; NONHUMAN; PROTEIN SYNTHESIS; RIBOSOME; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; PROTEIN SYNTHESIS INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS);

EID: 2442503394     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.03.091     Document Type: Article

References (12)

1. Felmingham D., Reinert R.R., Hirakata Y., Rodloff A. J. Antimicrob. Chemother. 50(Suppl. S1):2002;25-37
2. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. N. Engl. J. Med. 341:1999;233
3. Cassell G.H., Mekalanos J. JAMA. 285:2001;601
4. Sutcliffe J.A. Bioorg. Med. Chem. Lett. 13:2003;4159
5. Dandliker P.J., Black-Schaefer C., Bui M., Cai Y., Cao Z., Chovan L.M., Clark R.F., Daly M.M., David C.A., Englund E.E., Hickman R.K., Kakavas S.J., Lerner C.G., Merta P., Nilius A.M., Pratt S.D., Ruan X., Saiki A.Y.C., Shen L.L., Soni N.B., Wagner R., Weitzberg M., Xuei X., Zhong P., Beutel B.A. Antimicrob. Agents Chemother. 47:2003;3831
6. Gootz T.D., Brighty K.E. Andriole V.T. The Quinolones. 1998;29-80 Academic, San Diego
7. Radl S., Bouzard D. Heterocycles. 34:1991;2143
8. Atarashi S., Imamura M., Kimura Y., Yoshida A., Hayakawa I. J. Med. Chem. 36:1993;3444
9. Pratt S.D., David C.A., Black-Schaefer C., Dandliker P.J., Xuei X., Warrior U., Burns D.J., Zhong P., Cao Z., Saiki A.Y.C., Lerner C.G., Chovan L.E., Soni N.B., Nilius A.M., Wagenaar F.L., Merta P.J., Traphagen L.M., Beutel B.A. J. Biomol. Screen. 9:2004;3
10. Bruggemann A.B., Coffman S.L., Rhomberg P., Hungh H., Almer L., Nilius A.M., Flamm R., Doern G.V. Antimicrob. Agents Chemother. 46:2002;680
11. Antibacterial activity was assessed using the broth microdilution method as described in the NCCLS guidelines. 2000. Methods for Dilution Antimicrobial Susceptibility Testing. Approved Standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA
12. Ester 1b (Table 1, entry 2) exhibited modest antibacterial activity against H. influenzae GYR 1435 (32 mg/mL) but was inactive against a broader panel of both Gram-negative and Gram-positive bacterial strains